CABALETTA BIO, INC. Research and Development Expense
CABALETTA BIO, INC. (CABA) reported Research and Development Expense of $44.43 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- CABALETTA BIO, INC. research and development expense for the quarter ending 2026-06-30 was $44.43M, a 18.05% increase year-over-year.
- CABALETTA BIO, INC. research and development expense for the quarter ending 2026-03-31 was $37.35M, a 28.72% increase year-over-year.
- CABALETTA BIO, INC. research and development expense for the quarter ending 2025-12-31 was $36.19M, a 41.76% increase year-over-year.
- CABALETTA BIO, INC. research and development expense for the quarter ending 2025-09-30 was $39.82M, a 51.48% increase year-over-year.
- CABALETTA BIO, INC. research and development expense for fiscal 2025 was $142.67M, a 46.78% increase from fiscal 2024.
- CABALETTA BIO, INC. research and development expense for fiscal 2024 was $97.20M, a 75.38% increase from fiscal 2023.
- CABALETTA BIO, INC. research and development expense for fiscal 2023 was $55.42M, a 41.03% increase from fiscal 2022.
- CABALETTA BIO, INC. research and development expense for fiscal 2022 was $39.30M, a 20.95% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $44.43M 10-Q · filed 2026-08-13 | $81.78M 10-Q · filed 2026-08-13 | $117.98M derived: sum of 3 quarters · filed 2026-08-13 | $157.80M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $37.35M 10-Q · filed 2026-05-14 | $73.55M derived: sum of 2 quarters · filed 2026-05-14 | $113.37M derived: sum of 3 quarters · filed 2026-05-14 | $151.01M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $36.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $76.02M derived: sum of 2 quarters · filed 2026-03-23 | $113.66M derived: sum of 3 quarters · filed 2026-08-13 | $142.67M 10-K · filed 2026-03-23 |
| 2025-09-30 | $39.82M 10-Q · filed 2025-11-10 | $77.46M derived: sum of 2 quarters · filed 2026-08-13 | $106.48M 10-Q · filed 2025-11-10 | $132.01M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $37.64M 10-Q · filed 2026-08-13 | $66.66M 10-Q · filed 2026-08-13 | $92.19M derived: sum of 3 quarters · filed 2026-08-13 | $118.48M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $29.02M 10-Q · filed 2026-05-14 | $54.55M derived: sum of 2 quarters · filed 2026-05-14 | $80.84M derived: sum of 3 quarters · filed 2026-05-14 | $104.27M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $25.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $51.82M derived: sum of 2 quarters · filed 2026-03-23 | $75.25M derived: sum of 3 quarters · filed 2026-03-23 | $97.20M 10-K · filed 2026-03-23 |
| 2024-09-30 | $26.29M 10-Q · filed 2025-11-10 | $49.72M derived: sum of 2 quarters · filed 2025-11-10 | $71.67M 10-Q · filed 2025-11-10 | $89.08M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $23.43M 10-Q · filed 2025-08-07 | $45.38M 10-Q · filed 2025-08-07 | $62.79M derived: sum of 3 quarters · filed 2025-08-07 | $76.57M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $21.95M 10-Q · filed 2025-05-15 | $39.36M derived: sum of 2 quarters · filed 2025-05-15 | $53.15M derived: sum of 3 quarters · filed 2025-05-15 | $64.94M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $17.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $31.19M derived: sum of 2 quarters · filed 2025-03-31 | $42.99M derived: sum of 3 quarters · filed 2025-03-31 | $55.42M 10-K · filed 2025-03-31 |
| 2023-09-30 | $13.79M 10-Q · filed 2024-11-14 | $25.58M derived: sum of 2 quarters · filed 2024-11-14 | $38.02M 10-Q · filed 2024-11-14 | $50.42M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $11.80M 10-Q · filed 2024-08-08 | $24.23M 10-Q · filed 2024-08-08 | $36.63M derived: sum of 3 quarters · filed 2024-08-08 | $44.85M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $12.44M 10-Q · filed 2024-05-15 | $24.84M derived: sum of 2 quarters · filed 2024-05-15 | $33.05M derived: sum of 3 quarters · filed 2024-05-15 | $42.56M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $12.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $20.62M derived: sum of 2 quarters · filed 2024-03-21 | $30.13M derived: sum of 3 quarters · filed 2024-03-21 | $39.30M 10-K · filed 2024-03-21 |
| 2022-09-30 | $8.22M 10-Q · filed 2023-11-09 | $17.73M derived: sum of 2 quarters · filed 2023-11-09 | $26.90M 10-Q · filed 2023-11-09 | $36.82M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $9.51M 10-Q · filed 2023-08-10 | $18.68M 10-Q · filed 2023-08-10 | $28.60M derived: sum of 3 quarters · filed 2023-08-10 | $36.77M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $9.17M 10-Q · filed 2023-05-11 | $19.09M derived: sum of 2 quarters · filed 2023-05-11 | $27.26M derived: sum of 3 quarters · filed 2023-05-11 | $35.11M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $9.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $18.09M derived: sum of 2 quarters · filed 2023-03-16 | $25.94M derived: sum of 3 quarters · filed 2023-03-16 | $32.49M 10-K · filed 2023-03-16 |
| 2021-09-30 | $8.17M 10-Q · filed 2022-11-10 | $16.02M derived: sum of 2 quarters · filed 2022-11-10 | $22.57M 10-Q · filed 2022-11-10 | $28.35M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $7.85M 10-Q · filed 2022-08-11 | $14.41M 10-Q · filed 2022-08-11 | $20.18M derived: sum of 3 quarters · filed 2022-08-11 | $25.83M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $6.56M 10-Q · filed 2022-05-12 | $12.33M derived: sum of 2 quarters · filed 2022-05-12 | $17.98M derived: sum of 3 quarters · filed 2022-05-12 | $23.31M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $5.78M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $11.43M derived: sum of 2 quarters · filed 2022-03-17 | $16.76M derived: sum of 3 quarters · filed 2022-03-17 | $21.38M 10-K · filed 2022-03-17 |
| 2020-09-30 | $5.65M 10-Q · filed 2021-11-01 | $10.98M derived: sum of 2 quarters · filed 2021-11-01 | $15.60M 10-Q · filed 2021-11-01 | $18.63M derived: sum of 4 quarters · filed 2021-11-01 |
| 2020-06-30 | $5.33M 10-Q · filed 2021-08-05 | $9.95M 10-Q · filed 2021-08-05 | $12.98M derived: sum of 3 quarters · filed 2021-08-05 | $16.20M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $4.62M 10-Q · filed 2021-05-03 | $7.65M derived: sum of 2 quarters · filed 2021-05-03 | $10.87M derived: sum of 3 quarters · filed 2021-05-03 | $13.53M derived: sum of 4 quarters · filed 2021-05-03 |
| 2019-12-31 | $3.03M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $6.25M derived: sum of 2 quarters · filed 2021-03-16 | $8.91M derived: sum of 3 quarters · filed 2021-03-16 | $11.67M 10-K · filed 2021-03-16 |
| 2019-09-30 | $3.22M 10-Q · filed 2020-11-10 | $5.88M derived: sum of 2 quarters · filed 2020-11-10 | $8.64M 10-Q · filed 2020-11-10 | $9.88M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | $2.66M 10-Q · filed 2020-08-06 | $5.42M 10-Q · filed 2020-08-06 | $6.66M derived: sum of 3 quarters · filed 2020-08-06 | $9.25M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $2.76M 10-Q · filed 2020-05-12 | $4.00M derived: sum of 2 quarters · filed 2020-05-12 | $6.59M derived: sum of 3 quarters · filed 2020-05-12 | |
| 2018-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $3.83M derived: sum of 2 quarters · filed 2020-03-30 | $4.47M 10-K · filed 2020-03-30 | |
| 2018-09-30 | $2.59M 10-Q · filed 2019-12-05 | $3.23M 10-Q · filed 2019-12-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |